Only a few weeks after withdrawing one public offering due to market conditions, Nastech Pharmaceutical Company Inc. did a complete turnaround, pricing more than 1.7 million shares on Thursday to raise $23.3 million. (BioWorld Today)
Four months ago Ortho-McNeil Pharmaceuticals Inc. said it was acquiring Peninsula Pharmaceuticals Inc. for $245 million. But the merger left behind Peninsula's lead antibiotic, which went on to become the lead product for spinout Cerexa. (BioWorld Today)
As potential eye drug competitor Lucentis nears market, Eyetech Pharmaceuticals Inc. agreed to merge with OSI Pharmaceuticals Inc., bringing along its approved product Macugen, in a deal worth $935 million - or $20 a share, a 43 percent premium over Eyetech's closing stock price on Friday. (BioWorld Today)
Following a 17 percent stock slide Monday after the National Cancer Institute announced plans to amend the clinical trial protocols for 17-AAG and KOS-1022, Kosan Biosciences Inc. terminated its $39.4 million public offering priced just last week. (BioWorld Today)
